This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

aaiPharma Loses a Fan

In another illustration of the fading fortunes of aaiPharma (AAII), a onetime Wall Street fan has dropped his coverage of the company.

Adam Greene of First Albany Capital, told clients Tuesday he was no longer tracking the Wilmington, N.C. drug company "given the inability to make any reliable forecasts." He said that aaiPharma's announcement Monday that it was investigating "unusual sales" of two products last year "raises questions about the company's future direction."

The company yesterday also withdrew its revenue and sales guidance for the first quarter and for all of 2004, adding that it might have to re-state financial results for 2003, depending on the outcome of an investigation by outside directors and an independent law firm.

The announcement crushed aaiPharma's stock, which fell 36% to $9.77 on Monday, well below its recent 52-week high of $31.85. Shares gained 10 cents, or 1%, to $9.87.

Analysts drop coverage of companies all the time for many reasons, but Greene's decision is notable because he had been one of aaiPharma's biggest backers. He started following aaiPharma last May with a strong buy rating. He cut the rating to buy in December. Four weeks ago, he dropped his rating to neutral after aaiPharma set up a $15.9 million reserve against revenue for 2003's fourth quarter to reflect a significant number of product returns. (He doesn't own shares, but his firm is a market maker in aaiPharma's stock.)

Greene's action follows a decision by Standard & Poor's Corp. late Monday to revise its opinion on aaiPharma to negative from stable. The rating agency changed its outlook after the markets had closed.

S&P also reaffirmed below-investment grade ratings on corporate credit (B-plus), senior secured debt (BB-minus) and subordinated debt (B-minus), which it said reflected "limited growth potential" as well as its "aggressive use" of debt to finance product acquisitions. (The lowest investment grade rating is BBB-minus).
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs